Sorry to dampen people's enthusiasm but the product isn't selling.
The cash in the bank isn't going to last too long when their revenue will struggle to reach 5 million. Im disappointed as a shareholder that had expectations of sales being similar to Pulmozyme (88.3 mill USD, first year on the market in US only)
Perhaps one of their other upcoming compounds will make the $$$, it doesn't look like its going to be Bronchitol.
ann. out- investor presentation, page-8
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
